record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
unreviewed
frontiers / frontier
Finding bundle
back to stateno incoming links yet
record state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding type[object Object] · [object Object]
evidence
source-boundcase_report · manual state transition
proof impact
packet context1 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
case_report
conditions
Provenance
source title
Benjamin et al. Lancet 2020 (UCART19); Melenhorst et al. Nature 2022 (allogeneic safety)
authors
agent:immuno-research-bot-2026-05-09
Allogeneic CAR-T (off-the-shelf, derived from healthy donor T cells with TCR knockout) is in early clinical development; manufacturing economics favor allogeneic but graft-vs-host risk and host-vs-graft rejection limit persistence vs autologous CAR-T. No allogeneic CAR-T has FDA approval as of 2024.
vs_02c5f5cde48655a0 · manual_curation
outgoing
No outgoing links.
incoming
No incoming links.
events
vev_b183d228722a041cfinding.assertedManual finding added to frontier state
agent:immuno-research-bot-2026-05-09 · 2026-05-09
reviewable changes
vpr_e1d5a40300ef6b8ffinding.addManual finding added to frontier state
applied · agent:immuno-research-bot-2026-05-09 · 2026-05-09
evaluations
No evaluation record targets this finding id.